Full Text
The Full Text of this article is available as a PDF (88.4 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
Adenis A., Vanlemmens L., Fournier C., Hecquet B., Bonneterre J. Does induction chemotherapy with a mitoxantrone/vinorelbine regimen allow a breast-conservative treatment in patients with operable locoregional breast cancer? A French Northern Oncology Group trial in 105 patients. French Northern Oncology Group. Breast Cancer Res Treat. 1996;40(2):161–169. doi: 10.1007/BF01806211.
Ashizawa T., Miyoshi K., Asada M., Kobayashi E., Okabe M., Morimoto M., Gomi K., Hirata T. [Antitumor activity of navelbine (vinorelbine ditartrate), a new vinca alkaloid analog]. Gan To Kagaku Ryoho. 1993 Jan;20(1):59–66.
Baldini E., Tibaldi C., Ardizzoni A., Salvati F., Antilli A., Portalone L., Barbera S., Romano F., De Marinis F., Migliorino M. R. Cisplatin-vindesine-mitomycin (MVP) vs cisplatin-ifosfamide-vinorelbine (PIN) vs carboplatin-vinorelbine (CaN) in patients with advanced non-small-cell lung cancer (NSCLC): a FONICAP randomized phase II study. Italian Lung Cancer Task Force (FONICAP). Br J Cancer. 1998 Jun;77(12):2367–2370. doi: 10.1038/bjc.1998.393.
Besenval M., Delgado M., Demarez J. P., Krikorian A. Safety and tolerance of Navelbine in phase I-II clinical studies. Semin Oncol. 1989 Apr;16(2 Suppl 4):37–40.
Binet S., Chaineau E., Fellous A., Lataste H., Krikorian A., Couzinier J. P., Meininger V. Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubules. Int J Cancer. 1990 Aug 15;46(2):262–266. doi: 10.1002/ijc.2910460220.
Binet S., Fellous A., Lataste H., Krikorian A., Couzinier J. P., Meininger V. In situ analysis of the action of Navelbine on various types of microtubules using immunofluorescence. Semin Oncol. 1989 Apr;16(2 Suppl 4):5–8.
Boré P., Rahmani R., van Cantfort J., Focan C., Cano J. P. Pharmacokinetics of a new anticancer drug, navelbine, in patients. Comparative study of radioimmunologic and radioactive determination methods. Cancer Chemother Pharmacol. 1989;23(4):247–251. doi: 10.1007/BF00451650.
Bruno S., Puerto V. L., Mickiewicz E., Hegg R., Texeira L. C., Gaitan L., Martinez L., Fernandez O., Otero J., Kesselring G. Phase II trial of weekly i.v. vinorelbine as a single agent in first-line advanced breast cancer chemotherapy. The Latin-American experience. Am J Clin Oncol. 1995 Oct;18(5):392–396. doi: 10.1097/00000421-199510000-00006.
Canobbio L., Boccardo F., Pastorino G., Brema F., Martini C., Resasco M., Santi L. Phase-II study of Navelbine in advanced breast cancer. Semin Oncol. 1989 Apr;16(2 Suppl 4):33–36.
Colucci G., Gebbia V., Galetta D., Riccardi F., Cariello S., Gebbia N. Cisplatin and vinorelbine followed by ifosfamide plus epirubicin vs the opposite sequence in advanced unresectable stage III and metastatic stage IV non-small-cell lung cancer: a prospective randomized study of the Southern Italy Oncology Group (GOIM). Br J Cancer. 1997;76(11):1509–1517. doi: 10.1038/bjc.1997.586.
Cros S., Wright M., Morimoto M., Lataste H., Couzinier J. P., Krikorian A. Experimental antitumor activity of Navelbine. Semin Oncol. 1989 Apr;16(2 Suppl 4):15–20.
Cvitkovic E., Izzo J. The current and future place of vinorelbine in cancer therapy. Drugs. 1992;44 (Suppl 4):36–69. doi: 10.2165/00003495-199200444-00005.
Debal V., Morjani H., Millot J. M., Angiboust J. F., Gourdier B., Manfait M. Determination of vinorelbine (Navelbine) in tumour cells by high-performance liquid chromatography. J Chromatogr. 1992 Oct 2;581(1):93–99. doi: 10.1016/0378-4347(92)80451-u.
Depierre A., Lemarie E., Dabouis G., Garnier G., Jacoulet P., Dalphin J. C. A phase II study of Navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. Am J Clin Oncol. 1991 Apr;14(2):115–119. doi: 10.1097/00000421-199104000-00004.
Devizzi L., Santoro A., Bonfante V., Viviani S., Balzarini L., Valagussa P., Bonadonna G. Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin's disease. Ann Oncol. 1994 Nov;5(9):817–820. doi: 10.1093/oxfordjournals.annonc.a059010.
Dieras V., Extra J. M., Bellissant E., Espie M., Morvan F., Pierga J. Y., Mignot L., Tresca P., Marty M. Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method. J Clin Oncol. 1996 Dec;14(12):3097–3104. doi: 10.1200/JCO.1996.14.12.3097.
Dubos C., Prévost J. N., Brun J., Rousselot P. Infarctus myocardique et vinorelbine. Rapport d'un cas. Rev Mal Respir. 1991;8(3):299–300.
Felip E., Del Campo J. M., Bodi R., Vera R., Casado S., Rubio D. Cisplatin and vinorelbine followed by radiotherapy in the treatment of stage III-B non-small-cell lung cancer patients. Am J Clin Oncol. 1997 Aug;20(4):404–406. doi: 10.1097/00000421-199708000-00017.
Frasci G., Panza N., Comella P., Nicolella G. P., Natale M., Pacilio C., Gravina A., Caputi V., Botti G., Comella G. Cisplatin, gemcitabine and vinorelbine in locally advanced or metastatic non-small-cell lung cancer: a phase I study. Ann Oncol. 1997 Oct;8(10):1045–1048. doi: 10.1023/a:1008218306355.
Fumoleau P., Delgado F. M., Delozier T., Monnier A., Gil Delgado M. A., Kerbrat P., Garcia-Giralt E., Keiling R., Namer M., Closon M. T. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol. 1993 Jul;11(7):1245–1252. doi: 10.1200/JCO.1993.11.7.1245.
Furuse K., Kubota K., Kawahara M., Ogawara M., Kinuwaki E., Motomiya M., Nishiwaki Y., Niitani H., Sakuma A. A phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancer. Japan Vinorelbine Lung Cancer Study Group. Lung Cancer. 1994 Dec;11(5-6):385–391. doi: 10.1016/0169-5002(94)92167-9.
García-Conde J., Lluch A., Martin M., Casado A., Gervasio H., De Oliveira C., De Pablo J. L., Gorostiaga J., Girón G. C., Cervantes A. Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol. 1994 Nov;5(9):854–857. doi: 10.1093/oxfordjournals.annonc.a059019.
Gebbia V., Caruso M., Valenza R., Testa A., Cannata G., Verderame F., Cipolla C., Curto G., Oliveri D., Chiarenza M. Vinorelbine plus cisplatinum for the treatment of stage IIIB and IV non small cell lung carcinoma. Anticancer Res. 1994 May-Jun;14(3B):1247–1249.
Gershenson D. M., Burke T. W., Morris M., Bast R. C., Guaspari A., Hohneker J., Wharton J. T. A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer. Gynecol Oncol. 1998 Sep;70(3):404–409. doi: 10.1006/gyno.1998.5130.
Gridelli C., Perrone F., Gallo C., De Marinis F., Ianniello G., Cigolari S., Cariello S., Di Costanzo F., D'Aprile M., Rossi A. Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study. Eur J Cancer. 1997 Mar;33(3):392–397. doi: 10.1016/s0959-8049(97)89011-9.
Gridelli C., Perrone F., Ianniello G. P., Brancaccio L., Iaffaioli R. V., Curcio C., D'Aprile M., Cioffi R., Cigolari S., Rossi A. Carboplatin plus vinorelbine, a new well-tolerated and active regimen for the treatment of extensive-stage small-cell lung cancer: a phase II study. Gruppo Oncologico Centro-Sud-Isole. J Clin Oncol. 1998 Apr;16(4):1414–1419. doi: 10.1200/JCO.1998.16.4.1414.
Haldar S., Jena N., Croce C. M. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci U S A. 1995 May 9;92(10):4507–4511. doi: 10.1073/pnas.92.10.4507.
JOHNSON I. S., WRIGHT H. F., SVOBODA G. H., VLANTIS J. Antitumor principles derived from Vinca rosea Linn. I. Vincaleukoblastine and leurosine. Cancer Res. 1960 Aug;20:1016–1022.
Jehl F., Debs J., Herlin C., Quoix E., Gallion C., Monteil H. Determination of navelbine and desacetylnavelbine in biological fluids by high-performance liquid chromatography. J Chromatogr. 1990 Jan 26;525(1):225–233. doi: 10.1016/s0378-4347(00)83397-6.
Jehl F., Quoix E., Leveque D., Pauli G., Breillout F., Krikorian A., Monteil H. Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography. Cancer Res. 1991 Apr 15;51(8):2073–2076.
Kobayashi S., Sakai T., Dalrymple P. D., Wood S. G., Chasseaud L. F. Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs. Arzneimittelforschung. 1993 Dec;43(12):1367–1377.
Le Chevalier T., Brisgand D., Douillard J. Y., Pujol J. L., Alberola V., Monnier A., Riviere A., Lianes P., Chomy P., Cigolari S. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol. 1994 Feb;12(2):360–367. doi: 10.1200/JCO.1994.12.2.360.
Levêque D., Jehl F., Quoix E., Breillout F. Clinical pharmacokinetics of vinorelbine alone and combined with cisplatin. J Clin Pharmacol. 1992 Dec;32(12):1096–1098.
Levêque D., Quoix E., Dumont P., Massard G., Hentz J. G., Charloux A., Jehl F. Pulmonary distribution of vinorelbine in patients with non-small-cell lung cancer. Cancer Chemother Pharmacol. 1993;33(2):176–178. doi: 10.1007/BF00685338.
Marquet P., Lachatre G., Debord J., Eichler B., Bonnaud F., Nicot G. Pharmacokinetics of vinorelbine in man. Eur J Clin Pharmacol. 1992;42(5):545–547. doi: 10.1007/BF00314866.
Masters G. A., Hoffman P. C., Drinkard L. C., Samuels B. L., Golomb H. M., Vokes E. E. A review of ifosfamide and vinorelbine in advanced non-small cell carcinoma of the lung. Semin Oncol. 1998 Feb;25(1 Suppl 2):8–14.
Morris M., Brader K. R., Levenback C., Burke T. W., Atkinson E. N., Scott W. R., Gershenson D. M. Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix. J Clin Oncol. 1998 Mar;16(3):1094–1098. doi: 10.1200/JCO.1998.16.3.1094.
Mouridsen H. T. Systemic therapy of advanced breast cancer. Drugs. 1992;44 (Suppl 4):17–69. doi: 10.2165/00003495-199200444-00003.
Paintrand M. R., Pignot I. Navelbine: an ultrastructural study of its effects. J Electron Microsc (Tokyo) 1983;32(2):115–124.
Rahmani R., Martin M., Barbet J., Cano J. P. Radioimmunoassay and preliminary pharmacokinetic studies in rats of 5'-noranhydrovinblastine (navelbine). Cancer Res. 1984 Dec;44(12 Pt 1):5609–5613.
Rittenberg C. N., Gralla R. J., Rehmeyer T. A. Assessing and managing venous irritation associated with vinorelbine tartrate (Navelbine) Oncol Nurs Forum. 1995 May;22(4):707–710.
Romero A., Rabinovich M. G., Vallejo C. T., Perez J. E., Rodriguez R., Cuevas M. A., Machiavelli M., Lacava J. A., Langhi M., Romero Acuña L. Vinorelbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol. 1994 Feb;12(2):336–341. doi: 10.1200/JCO.1994.12.2.336.
Santomaggio C., Tucci E., Rinaldini M., Algeri R., Righi R., Pepi F., Ghezzi P., Andrei A., Bellezza A. Carboplatin and vinorelbine in the treatment of advanced non-small-cell lung cancer: a multicenter phase II study. Am J Clin Oncol. 1998 Feb;21(1):67–71. doi: 10.1097/00000421-199802000-00015.
Smith T. J., Hillner B. E., Neighbors D. M., McSorley P. A., Le Chevalier T. Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer. J Clin Oncol. 1995 Sep;13(9):2166–2173. doi: 10.1200/JCO.1995.13.9.2166.
Spielmann M., Dorval T., Turpin F., Antoine E., Jouve M., Maylevin F., Lacombe D., Rouesse J., Pouillart P., Tursz T. Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer. J Clin Oncol. 1994 Sep;12(9):1764–1770. doi: 10.1200/JCO.1994.12.9.1764.
Terenziani M., Demicheli R., Brambilla C., Ferrari L., Moliterni A., Zambetti M., Caraceni A., Martini C., Bonadonna G. Vinorelbine: an active, non cross-resistant drug in advanced breast cancer. Results from a phase II study. Breast Cancer Res Treat. 1996;39(3):285–291. doi: 10.1007/BF01806156.
Tononi A., Panzini I., Oliverio G., Pasquini E., Gianni L., Nicolini M., Ravaioli A. Vinorelbine chemotherapy in non small cell lung cancer: experience in elderly patients. J Chemother. 1997 Aug;9(4):304–308. doi: 10.1179/joc.1997.9.4.304.
Twelves C. J., Dobbs N. A., Curnow A., Coleman R. E., Stewart A. L., Tyrrell C. J., Canney P., Rubens R. D. A phase II, multicentre, UK study of vinorelbine in advanced breast cancer. Br J Cancer. 1994 Nov;70(5):990–993. doi: 10.1038/bjc.1994.435.
Van Belle S. J., De Smet M., Monsaert C., Geerts F., Storme G. A., Massart D. L. High-performance liquid chromatographic determination of navelbine in MO4 mouse fibrosarcoma cells and biological fluids. J Chromatogr. 1992 May 8;576(2):351–357. doi: 10.1016/0378-4347(92)80211-8.
Veronesi A., Crivellari D., Magri M. D., Cartei G., Mansutti M., Foladore S., Monfardini S. Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients. Eur J Cancer. 1996 Sep;32A(10):1809–1811. doi: 10.1016/0959-8049(96)00190-6.
Vogel C., O'Rourke M., Winer E., Hochster H., Chang A., Adamkiewicz B., White R., McGuirt C. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol. 1999 Apr;10(4):397–402. doi: 10.1023/a:1008364222793.
Wang L. G., Liu X. M., Kreis W., Budman D. R. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol. 1999;44(5):355–361. doi: 10.1007/s002800050989.
Weber B. L., Vogel C., Jones S., Harvey H., Hutchins L., Bigley J., Hohneker J. Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol. 1995 Nov;13(11):2722–2730. doi: 10.1200/JCO.1995.13.11.2722.
Weisenberg R. C. Microtubule formation in vitro in solutions containing low calcium concentrations. Science. 1972 Sep 22;177(4054):1104–1105. doi: 10.1126/science.177.4054.1104.
Wozniak A. J., Crowley J. J., Balcerzak S. P., Weiss G. R., Spiridonidis C. H., Baker L. H., Albain K. S., Kelly K., Taylor S. A., Gandara D. R. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol. 1998 Jul;16(7):2459–2465. doi: 10.1200/JCO.1998.16.7.2459.